The Four-Year Gap
Women are diagnosed later than men for more than 700 diseases. The femtech diagnostic boom is a direct response to a measurable failure of the evidence base.
A population-wide analysis covering two decades of health records found that women, on average, receive a diagnosis four years later than men across more than 700 distinct conditions. The figure was surfaced in the World Economic Forum's Women's Health Investment Outlook 2026, published in May, and it is the most precise quantification yet of a gap the industry has discussed in qualitative terms for years.
Four years is not a clinical inconvenience. It is the difference between an endometriosis diagnosis at 24 and one at 33. It is the difference between a heart attack treated in the catheter lab and one written off as anxiety in an emergency room. It is, in aggregate, a structural feature of modern medicine.
The cause is not mystery. It is measurement.
The data gap that built the diagnostic gap
Roughly 5% of clinical trials report results disaggregated by sex, according to the WEF's March 2026 analysis.
A 2023 Nature investigation of US National Institutes of Health funding data showed the same pattern in the upstream research pipeline: conditions that disproportionately affect women, including migraine, endometriosis, ME/CFS, and anxiety disorders, receive funding well below what their disease burden would warrant.
The ratio of funding to disease burden for ME/CFS, a condition that disproportionately affects women, is 0.04. For HIV/AIDS, which disproportionately affects men, the ratio is 15.6. A nearly four-hundred-fold differential, hidden inside what looks, at the topline, like an equitable research system.
When upstream research is calibrated to male physiology, downstream clinical decision-making inherits the calibration. Symptom presentations that diverge from the male baseline get coded as atypical, psychosomatic, or premenstrual. Diagnostic algorithms trained on male-dominant datasets miss what they were never taught to see. The four-year lag is what that looks like when measured at the population scale.
The structural gap is the reason women's health diagnostics has become one of the most capital-attractive verticals in the category. The breast cancer and women's oncology cluster alone has raised over $280 million in recent years across companies including Mercy BioAnalytics, PinkDx, Clairity, Ataraxis AI, and BeSounds Breast. At-home diagnostics players including Inito, Oova, Evvy, and NextGen Jane have collectively built a sub-category averaging roughly $24 million in cumulative funding per company, capital-efficient by femtech standards.
These companies are not selling products. They are selling time. Every quarter shaved off a diagnostic delay is a quarter of earlier intervention, earlier treatment, and lower lifetime cost of care. For employers and payers, that math is increasingly legible. For investors, it is the rare femtech thesis that translates cleanly into the language of unit economics.
The same WEF outlook notes that women's health still receives only 6% of private healthcare investment, despite women representing nearly half the global population. Boston Consulting Group has separately estimated that closing the gap in four under-addressed therapeutic areas alone, cardiovascular disease, osteoporosis, menopause, and Alzheimer's, represents more than $100 billion in US market opportunity by 2030.
The capital is moving. The diagnostic infrastructure is being rebuilt. But the underlying research bias that produced the four-year gap has not been corrected, and until trial design changes upstream, every diagnostic built downstream is doing remedial work on a system that was never engineered to see women in the first place.
That is the femtech diagnostic thesis, stated plainly. The category is not solving a women's health problem. It is patching a measurement failure.
---
The Luteal is an intelligence publication covering the femtech and women's health industry. Subscribe at theluteal.com.